Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial
Main Article Content
Keywords
psoriasis, moderate to severe, POETYK, deucravacitinib, TYK2 inhibitor
Abstract
N/A
References
2. Armstrong AW, et al. [poster] Presented at the American Academy of Dermatology Annual Meeting, March 25–29, 2022,
Boston, MA.
3. Armstrong AW, et al. J Dermatolog Treat. 2017;28:200-205.
4. Bushmakin AG, et al. Qual Life Res. 2011;20:491-498.
5. Warren RB, et al. J Eur Acad Dermatol Venereol. 2021;35:450-457.
6. Blauvelt A, et al. J Manag Care Spec Pharm. 2021;27:84-94.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.